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Objective: Although lung transplantation is viewed as an acceptable option for
patients with end-stage idiopathic pulmonary fibrosis, the survival benefit of this
approach is still debated. This study examined whether there was a survival benefit
of lung transplantation in a cohort of patients referred to our transplant center with
a diagnosis of idiopathic pulmonary fibrosis according to American Thoracic
Society criteria.
Methods: Forty-six patients accepted for lung transplantation during a 12-year
period with a diagnosis of idiopathic pulmonary fibrosis form the basis of this study.
Survival benefit offered by lung transplantation was assessed using Cox propor-
tional-hazards modeling, with patients on a waiting list as the control group.
Results: Twenty-eight patients underwent lung transplantation (27 single and 1
double), 16 patients died while waiting, and 2 patients remained on the active
waiting list. Diagnosis of idiopathic pulmonary fibrosis was made on histologic
examination of the explanted lung or lung biopsy before lung transplantation. There
was a pattern of usual interstitial pneumonia in 31 cases (67%). The 15 remaining
patients fulfilled all American Thoracic Society criteria for idiopathic pulmonary
fibrosis. The median waiting time for organs was 51 days. Survival after lung
transplantation was 79.4% at 1 year, 63.5% at 2 years, and 39% at 5 years. The
multivariable analysis showed that lung transplantation reduced the risk of death by
75% (95% confidence interval, 8%-86%; P  .03) after adjustment on potential
confounding variables.
Conclusions: Lung transplantation is effective in improving the survival of selected
patients affected by idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal form ofinterstitial lung disease.1-3 The median survival of patients with IPF rangesfrom 2.84 to 4.8 years5 after diagnosis, depending on the stage of thedisease,5,6 histopathologic features,7 and response to medical treatment.The course of the disease is not easily predictable because of the variablerates of progression from patient to patient. This poor prognosis is ex-
plained by the poor responsiveness to currently available treatments including
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steroids and cytotoxic agents. Conversely, lung transplan-
tation (LTx) has been demonstrated to be a viable option in
these patients, the median of survival being approximately
36 months in the International Registry.8 In comparison
with natural history, the survival benefit conferred by LTx
in case of pulmonary fibrosis has been suggested,9-11 but the
question has not been answered definitively. In particular,
Hosenpud and colleagues11 compared the survival of pa-
tients on a waiting list and after LTx in the US Registry and
found that LTx conferred a survival benefit in cases of
interstitial pulmonary fibrosis. However, the difference in
survival did not reach statistical significance. Moreover, the
patients were classified with interstitial pulmonary fibrosis
irrespective of histologic considerations, which can be mis-
leading, because without LTx, the prognosis of various
types of interstitial lung diseases differs markedly.4,12 From
our own data, we assessed the survival benefit provided by
LTx in a homogeneous sample of patients with a diagnosis
of IPF according to American Thoracic Society (ATS)
criteria. By use of the Cox proportional-hazards modeling,
we analyzed the survival benefit offered by LTx in our
center, with patients on a waiting list as the control group.
Methods
Patients
From March 1988 to July 2001, 181 patients were accepted on a
waiting list for LTx at Hoˆpital Beaujon. Of these patients, 149
underwent LTx, and 32 died while waiting. We restricted our
analysis to 46 patients who had a diagnosis of IPF according to
ATS criteria.1 These patients form the basis of the study. Particular
attention was paid to exclude patients with a history of collagen
vascular disease, allergic alveolitis, exposure to mineral and or-
ganic dusts, or drug toxicity. All patients had been treated with
corticosteroids, some of them with various drug regimens (1 pa-
tient had received interferon gamma therapy, and 10 patients had
received immunosuppressive drugs [cyclophosphamide or azathio-
prine]) before referral to our institution. Selection of patients for
LTx was made according to international guidelines.13 Patients
with severe pulmonary hypertension (mean pulmonary artery pres-
sure  40 mm Hg) were not considered for transplantation in our
center.
Lung and Heart Physiology
Pulmonary function tests were performed according to the ATS
standards, and customary normal reference values were used for
spirometry, lung volumes, and diffusing capacity. Lung volumes
were measured by plethysmography. Exercise capacity was as-
sessed by a standardized 6-minute walk test. Left ventricular
ejection fraction was measured by gated equilibrium radionuclide
ventriculography after a peripheral intravenous injection of 750
MBq technetium-99m human serum albumin. Right heart cathe-
terization was performed in all patients using a standard technique.
Cardiac output was measured by the thermodilution technique.
Coronary angiography was performed when left heart dysfunction
was suspected.
Organ Allocation and Transplantation Procedure
When the organs became available, the decision on organ alloca-
tion was made by a senior member of the transplant team accord-
ing to the severity of each patient but irrespective of the waiting
time of each recipient. Donor selection was based on widely
accepted guidelines.14 Donor and recipient matching were based
on ABO compatibility and cytomegalovirus status. Single LTx was
performed using a classic technique,15 whereas bilateral LTx was
a bilateral sequential operation.16 Our policy was to perform single
LTx except in case of significant bronchiectasis. Immunosuppres-
sion was administered as previously described.17
Follow-up
Routine medical management was continued during the waiting
period under the supervision of the transplant physician. After
LTx, patients were seen at regular intervals at the outpatient clinic
and were asked to refer to the transplant center in case of unusual
symptoms or in case of functional impairment.
Statistical Analysis
Date of entry in the study was the date of listing for transplanta-
tion, and all measurements taken at this time were used in the
analysis. Continuous data are expressed as median (25th-75th
percentile), and categorical data are expressed as counts and pro-
portions. Survival after transplantation was estimated by the
Kaplan-Meier method. Cox proportional hazards regression was
used to assess the survival effect of LTx after adjustment on
potential confounders.18 All variables listed in Tables 1 and 2 were
TABLE 1. Characteristics of patients at time of acceptance for transplantation
Variables (units)
All patients
n  46
Patients who received
transplants
n  28
Patients who did not receive
transplants
n  16 P
Age (yr) 50.1 (44.0–58.3) 49.3 (41.3–55.6) 52.9 (48.3–60.3) .3
Male/female 33 (71.7%) 20 (71.4%) 11 (68.8%) .9
Height (cm) 172.0 (163.0–175.0) 174.0 (163.0–178.0) 168.5 (162.0–172.0) .07
Weight (kg) 73.0 (60.0–78.0) 76.0 (64.0–84.0) 63.5 (54.0–75.0) .03
Body mass index 24.7 (22.0–27.1) 25.7 (22.9–27.4) 23.7 (20.0–25.1) .06
Corticosteroid therapy (mg) 19.0 (10.0–25.0) 18.0 (10.0–20.0) 22.5 (4.5–45.0) .3
Corticosteroid therapy (n) 39 (84.8%) 25 (89.3%) 13 (81.3%) .7
Boldface indicates statistical significance.
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used in the analysis. LTx was included in the Cox regression
model as a time-dependent covariate. To enhance the accuracy of
the model, the number of variables considered for the final Cox
model was limited to 3 explanatory variables.19 Bootstrap resam-
pling was used for model building.20 A total of 1000 samples of
80% of the initial data set were drawn at random with replacement.
For each bootstrap sample, stepwise variable selection was per-
formed. The 3 most frequently selected variables were included in
the final model. Proportional hazards assumption was checked
using a graphic method (log-log plots) and residual analysis.18
Data analysis was performed with Stata Statistical Software: Re-
lease 7.0 (Stata Corporation, College Station, Tex).
Results
Among all patients with interstitial lung disease placed on
the waiting list during the study period, 46 patients were
retrospectively selected who met the ATS criteria. Of these
patients, 26 (56.5%) had a lung biopsy before LTx showing
a usual interstitial pneumonia (UIP) pattern, whereas no
biopsy was performed in 20 cases. For patients who under-
went LTx, the histologic examination of the explanted lung
allowed the diagnosis of UIP in 5 patients who did not
undergo biopsy before LTx. Fifteen patients in this study
did not have confirmation of IPF. However, these patients
fulfilled all the clinical, spirometric, and computed tomo-
graphic scan criteria of IPF defined by the ATS. Of the 46
patients with IPF placed on the waiting list, 28 (61%)
received transplants, 16 (35%) died while on the waiting
list, and 2 (4%) are currently waiting for transplantation.
Thirteen LTxs were performed during the first half of the
study, and 15 LTxs were performed during the second half.
Clinical characteristics of the patients are summarized in
Table 1. All were dyspneic at rest (New York Heart Asso-
ciation class IV) and were given continuous nasal oxygen
therapy. Consistent with their underlying advanced pulmo-
nary fibrosis, the patients had a severe restrictive spiromet-
ric pattern, impaired oxygenation, and poor exercise toler-
ance (Table 2). Two thirds of the patients had hypercapnia
at rest. The group of patients who underwent LTx and the
group of patients who died on the waiting list differed
significantly only by height and total lung capacity (Tables
1 and 2). In all but 1 case, the procedure was single LTx,
whereas sequential bilateral LTx was performed once be-
cause of significant bronchiectasis in both lungs. The me-
dian waiting time for organs for the 28 patients who under-
went LTx was 51 days (19-98 days). The median survival of
patients on the waiting list (from placement on the list to
death, patients being censored at time of transplant) was 136
TABLE 3. Multivariable regression values
Variables (units)
Hazard
ratio
95% confidence
interval P
TLC (mL) 0.99 0.99–1.01 .22
6-minute walk (m), by 50 m
increase
0.75 0.61–0.93 .003
Transplantation status* 0.25 0.08–0.86 .03
Boldface indicates statistical significance.
*Modeled as a time-dependent covariate.
TABLE 2. Cardiopulmonary features of patients when evaluated for lung transplantation
Variables (units)
All patients
n  46
Patients who received transplants
n  28
Patients who did not receive transplants
n  16 P
Pulmonary function
FVC, L 1370 (1000–1670) 1500 (1030–1750) 1160 (910–1500) .08
FVC, % 34.0 (26.0–41.0) 35.5 (29.0–42.0) 34.5 (26.0–41.0) .5
TLC, L* 2980 (2360–3300) 3110 (2580–3340) 2340 (2010–3130) .04
TLC, % 47.0 (39.0–54.0) 48.0 (43.0–55.0) 43.5 (35.0–53.0) .2
Gas exchange§
PaO2, mm Hg 47.0 (38.0–53.0) 45.0 (38.0–51.0) 51.0 (34.0–54.5) .9
PaCO2, mm Hg 45.0 (41.0–50.0) 45.0 (41.0–50.0) 44.0 (41.0–48.5) .5
Patients with hypercapnia 29 (63.0%) 16 (57.1%) 12 (75.0%) .3
Cardiac assessment
Left ventricle ejection fraction % 60.0 (54.5–70.0) 58.0 (53.0–71.0) 61.0 (58.0–69.0) .5
Right heart catheterization
PA systolic 40.0 (35.0–50.0) 41.0 (36.0–55.0) 40.0 (34.0–42.0) .3
PA diastolic 20.0 (16.0–25.0) 20.0 (15.0–25.0) 20.0 (17.0–24.0) .9
PA mean 28.0 (24.5–34.0) 28.0 (25.0–35.0) 28.0 (23.0–31.0) .6
Wedge 10.0 (8.0–15.0) 10.0 (7.0–14.0) 11.0 (8.0–16.0) .6
Cardiac index 3.0 (2.7–3.6) 3.2 (2.8–3.7) 2.8 (2.7–3.0) .06
Exercise tolerance
6-minute walk, m 190 (130–270) 184 (150–270) 145 (125–258) .2
Boldface indicates statistical significance. PA, Pulmonary artery; TLC, total lung capacity; FVC, forced vital capacity.
*Plethysmographic measurements.
§Room air; at rest.
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days (69-307 days). Survival after LTx (Figure 1) was 93%
at day 30, 79.4% at 1 year, 63.5% at 2 years, and 39% at 5
years. Figure 2 shows survival on the waiting list (ie,
survival from placement on the waiting list until death or
transplantation) compared with survival in the group of
patients who underwent LTx (ie, survival from placement
on the waiting list, including posttransplantation survival).
All the deaths in patients on the waiting list were ascribed to
respiratory failure. By multivariate analysis, only the
6-minute walk test and amount of oxygen supply at the time
Figure 1. Survival after LTx.
Figure 2. Survival on waiting list (from placement on the list to death or transplantation) compared with survival
of patients who underwent LTx (from placement on the list including posttransplantation survival).
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of inscription on the waiting list were found associated with
death in the patients on the waiting list. Of the 28 patients
receiving LTxs, 12 have died and 16 were alive at the end
of the study period. The causes of death were sepsis in 6
patients, chronic rejection in 4 patients, carcinoma in 1
patient, and primary graft failure in 1 patient. The 3 vari-
ables included in the final multivariable model were trans-
plantation status, total lung capacity, and 6-minute walk
test. In a multivariable analysis, only transplantation status
(hazard ratio [HR]: 0.25; 95% confidence interval [CI]:
0.08-0.86; P: 0.03) and 6-minute walk test (HR: 0.75; 95%;
CI: 0.61-0.93; P: .003) remain significantly associated with
mortality (Table 3).
Discussion
The main result of this study is that LTx in patients with IPF
allows a 75% (CI: 14%-92%) reduction in the risk of death
when the patients are accepted on our waiting list. Because
a randomized controlled trial comparing LTx with medical
management alone for patients with end-stage lung disease
seems unethical, various approaches may help in assessing
survival improvement given by LTx. The first approach is to
compare the survival of patients who underwent LTx with
that of a historical cohort of patients with several causes of
end-stage lung diseases.21 However, in that case, the 2
groups are not really comparable, because patients listed for
transplantation form a highly selected sample of patients. A
more appropriate approach is to compare survival rates
between patients receiving LTx with those remaining on the
waiting list.22 Such an approach may have some drawbacks,
because the 2 groups are not really comparable. On the one
hand, the patients who received transplants are in a way
more resistant than those who did not, because they are able
to wait until LTx, and on the other hand, some centers
attempt to give lung grafts to patients with the poorest life
expectancy. The best approach is probably the method pre-
viously used by Cox and Oakes,23 making a multivariable
model that includes transplantation as a time-dependent
covariate. This powerful model allows the introduction of
potential confounders to further reduce selection bias. Such
an approach has already been used in several stud-
ies.10,11,24,25 For example, Sharples and colleagues25 ana-
lyzed the survival of 67 patients with cystic fibrosis referred
for heart-lung transplantation. After adjustment for potential
confounders, they found that LTx for these patients de-
creased the risk of death by approximately 50%. However,
this result was not statistically significant. Using the same
statistical approach, Geertsma and colleagues10 studied 157
patients with various underlying lung diseases who were
listed for LTx. They found a 55% reduction of the risk of
death. However, they did not calculate a separate HR ac-
cording to the diagnosis. Among these patients, only 9 had
IPF. On the basis of data from the United Network for
Organ Sharing, Hosenpud and colleagues11 also analyzed
the effect of diagnosis on the survival benefit of LTx for
end-stage lung disease. The results were adjusted for race,
sex, and age by means of multivariable analysis. The clear-
est benefit occurred in the cystic fibrosis group, whereas it
was not significant for interstitial pulmonary fibrosis or
emphysema. In this latter study, IPF was not separated from
other interstitial lung diseases. More recently, Aurora and
colleagues24 studied 124 children with cystic fibrosis ac-
cepted for LTx during a 10-year period. After adjustment on
7 factors previously found as potential confounders, LTx
was significantly associated with a reduction of 69% in the
overall risk of death. By analyzing all the patients consec-
utively registered for first LTx on the Eurotransplant wait-
ing list for a 7-year period, De Meester and colleagues9
found a beneficial effect of LTx for patients with pulmonary
fibrosis (IPF and sarcoidosis), cystic fibrosis, emphysema,
and pulmonary hypertension. However, the methodologic
approach used raises several concerns. They used a time-
dependent nonproportional hazard analysis to assess the
benefit offered by transplantation. However, this model did
not take into account potential confounding variables, and
no test of statistical significance was provided.
Given these results, we decided to study the effect of
LTx on the survival of patients in a homogeneous sample of
patients listed for LTx in our center with a diagnosis of IPF.
Using Aurora and colleagues’ statistical approach,24 we
found a reduction of 75% in the risk of death after adjust-
ment for variables believed to be potential confounders. The
following assumptions and limitations to our study should
be emphasized. First, using a time-dependent proportional
hazard model, we assume a constant HR over time. These
limitations led Hosenpud and coworkers11 to use a time-
dependent nonproportional hazards analysis to assess the
role of LTx on survival. However, we paid critical attention
to check that this major assumption of the Cox model was
not violated. Graphic inspection of the log-log plots and
residual analysis did not detect a clear violation of propor-
tional hazards assumption. A second assumption in our
analysis is that in our model we took into account the major
risk factors for transplant-related mortality. In light of the
small study sample size, we chose to limit the number of
explanatory variables to 3. Although we included several
factors known to influence the survival of patients with
end-stage lung diseases or IPF, we cannot exclude the
possibility that other factors, not studied in our analysis or
unidentified, may have affected the outcome. Moreover, the
decision and timing of listing involve subjective events
difficult to account for. The small size of this study is of
concern. Including in the analysis all patients with intersti-
tial disease irrespective of its origin would have reinforced
the statistical power. However, it might have resulted in a
less homogeneous sample of patients leading to erroneous
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conclusions, because patients with secondary pulmonary
fibrosis have different prognoses than patients with IPF.12 In
the same way, we could have pooled our data with those of
other transplantation centers to increase the statistical power
of our study. However, we considered that this approach
would have led to a more heterogeneous sample, because
the participating centers were highly unlikely to have a
uniform listing policy for all patients. A third limitation is
the lack of histologic specimens showing a UIP pattern in
15 cases (10 patients who died before LTx and 5 patients
who underwent LTx). Although these patients fulfilled all
the ATS criteria for IPF, diagnosing without a histologic
specimen is less certain and could have introduced a bias in
the analysis. It must be noted that we did not consider LTx
in our center for patients with IPF when associated with
severe pulmonary hypertension. Because pulmonary hyper-
tension is associated with a decrease in posttransplant sur-
vival regardless of the underlying disease, our results should
be limited to patients with IPF and without significant
pulmonary hypertension.
The present study demonstrates the survival benefit of-
fered by LTx in patients with IPF. The influence of the
organ allocation scheme on our results must be emphasized.
The organ allocation scheme in use in France, as in other
countries,24 is not based on the waiting time of each recip-
ient. This policy allows the attending physician to prioritize
the patients with the poorest life expectancy. It results in a
very short waiting time for patients with IPF and in a longer
waiting time for patients with longer life expectancy. In
comparison, the median waiting time of the other patients
on our list is approximately 10 months. However, despite
this short waiting time, the fatality rate on the waiting list
remains high in patients with IPF. In our center, 35% of
patients with IPF died on the waiting list compared with
15% of patients with other diagnoses. The fatality rate of
our patients listed for LTx, which is much higher than that
described by Hosenpud and colleagues11 in the United Net-
work for Organ Sharing registry, helps to demonstrate a
beneficial effect of LTx in our study. This high fatality rate
could be relative to the very end stage of the disease at the
time of listing (New York Heart Association class IV,
hypercapnia at rest in the majority of patients, and depen-
dency on high flow of oxygen). Thus, we think that the
conclusion of our study should be restricted to centers with
the same organ allocation policy as ours. Among the vari-
ables studied, only exercise capacity assessed by the
6-minute walk test was associated with mortality. These
findings should be interpreted cautiously because we lack
statistical power to reliably assess predictors of mortality.
The aim of including these variables in this study was not to
study predictors of mortality for patients with IPF who were
listed for LTx but to control potential biases when assessing
the effect of LTx on survival.
Conclusion
Unless survival without transplantation improves dramati-
cally by means of new medical treatments, LTx seems to be
effective in reducing the risk of death for patients with IPF
without secondary pulmonary hypertension.
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